Based on the CITIUS PHARMAC. DL -001 stock forecast from 0 analysts, the average analyst target price for CITIUS PHARMAC. DL -001 is not available over the next 12 months. CITIUS PHARMAC. DL -001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of CITIUS PHARMAC. DL -001 is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, CITIUS PHARMAC. DL -001’s stock price was EUR 0.13. CITIUS PHARMAC. DL -001’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -99.22% over the last year.
No recent analyst target price found for CITIUS PHARMAC. DL -001
No recent average analyst rating found for CITIUS PHARMAC. DL -001
Company Overview CITIUS PHARMAC. DL -001
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey. Read Less
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its la...Read More
Frequently Asked Questions About CITIUS PHARMAC. DL -001 (47N:F) Stock
Stock Target Advisor's fundamental analysis for CITIUS PHARMAC. DL -001's stock is Bearish.
Unfortunately we do not have enough data on 47N:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 47N:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 47N:F's stock to indicate if its overvalued.
The last closing price of 47N:F's stock was EUR 0.13.
The most recent market capitalization for 47N:F is EUR 1.02M.
Unfortunately we do not have enough analyst data on 47N:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CITIUS PHARMAC. DL -001's stock.
As per our most recent records CITIUS PHARMAC. DL -001 has 22 Employees.
CITIUS PHARMAC. DL -001's registered address is 11 Commerce Drive, Cranford, NJ, United States, 07016.
You can get more information about it from CITIUS PHARMAC. DL -001's website at https://citiuspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About CITIUS PHARMAC. DL -001 (47N:F) Stock
Stock Target Advisor's fundamental analysis for CITIUS PHARMAC. DL -001's stock is Bearish.
Unfortunately we do not have enough data on 47N:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 47N:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 47N:F's stock to indicate if its overvalued.
The last closing price of 47N:F's stock was EUR 0.13.
The most recent market capitalization for 47N:F is EUR 1.02M.
Unfortunately we do not have enough analyst data on 47N:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CITIUS PHARMAC. DL -001's stock.
As per our most recent records CITIUS PHARMAC. DL -001 has 22 Employees.
CITIUS PHARMAC. DL -001's registered address is 11 Commerce Drive, Cranford, NJ, United States, 07016.
You can get more information about it from CITIUS PHARMAC. DL -001's website at https://citiuspharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 47N:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
